O	0	10	Randomized
O	11	17	active
O	17	18	-
O	18	28	controlled
O	29	34	phase
O	35	37	II
O	38	43	study
O	44	46	of
B-intervention	47	56	denosumab
O	57	65	efficacy
O	66	69	and
O	70	76	safety
O	77	79	in
O	80	88	patients
O	89	93	with
O	94	100	breast
O	101	107	cancer
O	107	108	-
O	108	115	related
O	116	120	bone
O	121	131	metastases
O	131	132	.

O	133	142	Denosumab
O	142	143	,
O	144	145	a
O	146	151	fully
O	152	157	human
O	158	168	monoclonal
O	169	177	antibody
O	178	180	to
O	181	189	receptor
O	190	199	activator
O	200	202	of
O	203	210	nuclear
O	211	217	factor
O	217	218	-
O	218	224	kappaB
O	225	231	ligand
O	231	232	,
O	233	243	suppresses
O	244	248	bone
O	249	259	resorption
O	259	260	.

O	261	263	In
O	264	268	this
O	269	274	study
O	274	275	,
O	276	278	we
O	279	288	evaluated
O	289	292	the
O	293	301	efficacy
O	302	305	and
O	306	312	safety
O	313	315	of
O	316	320	five
O	321	327	dosing
O	328	336	regimens
O	337	339	of
O	340	349	denosumab
O	350	352	in
B-eligibility	353	361	patients
I-eligibility	362	366	with
I-eligibility	367	373	breast
I-eligibility	374	380	cancer
I-eligibility	380	381	-
I-eligibility	381	388	related
I-eligibility	389	393	bone
I-eligibility	394	404	metastases
I-eligibility	405	408	not
I-eligibility	409	419	previously
I-eligibility	420	427	treated
I-eligibility	428	432	with
I-eligibility	433	444	intravenous
I-eligibility	445	460	bisphosphonates
I-eligibility	461	462	(
I-eligibility	462	464	IV
I-eligibility	465	468	BPs
I-eligibility	468	469	)
O	469	470	.

O	471	479	Eligible
O	480	485	women
O	486	487	(
O	487	488	n
O	489	490	=
B-total-participants	491	494	255
O	494	495	)
O	496	500	with
O	501	507	breast
O	508	514	cancer
O	514	515	-
O	515	522	related
O	523	527	bone
O	528	538	metastases
O	539	543	were
O	544	554	stratified
O	555	557	by
O	558	562	type
O	563	565	of
O	566	580	antineoplastic
O	581	588	therapy
O	589	597	received
O	598	601	and
O	602	610	randomly
O	611	619	assigned
O	620	622	to
O	623	626	one
O	627	629	of
O	630	633	six
O	634	641	cohorts
O	642	643	(
O	643	647	five
O	648	657	denosumab
O	658	665	cohorts
O	666	667	[
O	667	674	blinded
O	675	677	to
O	678	682	dose
O	683	686	and
O	687	696	frequency
O	696	697	]
O	697	698	;
B-control	699	702	one
I-control	703	707	open
I-control	707	708	-
I-control	708	713	label
I-control	714	716	IV
I-control	717	719	BP
O	720	726	cohort
O	726	727	)
O	727	728	.

O	729	738	Denosumab
O	739	742	was
O	743	755	administered
O	756	770	subcutaneously
O	771	776	every
O	777	778	4
O	779	784	weeks
O	785	786	(
O	786	788	30
O	788	789	,
O	790	793	120
O	793	794	,
O	795	797	or
O	798	801	180
O	802	804	mg
O	804	805	)
O	806	808	or
O	809	814	every
O	815	817	12
O	818	823	weeks
O	824	825	(
O	825	827	60
O	828	830	or
O	831	834	180
O	835	837	mg
O	837	838	)
O	838	839	.

O	840	843	The
O	844	851	primary
O	852	855	end
O	856	861	point
O	862	865	was
B-outcome-Measure	866	876	percentage
I-outcome-Measure	877	879	of
I-outcome-Measure	880	886	change
I-outcome-Measure	887	889	in
I-outcome-Measure	890	893	the
I-outcome-Measure	894	898	bone
I-outcome-Measure	899	907	turnover
I-outcome-Measure	908	914	marker
I-outcome-Measure	915	920	urine
I-outcome-Measure	921	922	N
I-outcome-Measure	922	923	-
I-outcome-Measure	923	934	telopeptide
I-outcome-Measure	935	944	corrected
I-outcome-Measure	945	948	for
I-outcome-Measure	949	954	urine
I-outcome-Measure	955	965	creatinine
I-outcome-Measure	966	967	(
I-outcome-Measure	967	971	uNTx
I-outcome-Measure	971	972	/
I-outcome-Measure	972	974	Cr
I-outcome-Measure	974	975	)
O	976	980	from
O	981	989	baseline
O	990	992	to
O	993	998	study
O	999	1003	week
O	1004	1006	13
O	1006	1007	.

O	1008	1011	The
B-outcome-Measure	1012	1022	percentage
I-outcome-Measure	1023	1025	of
I-outcome-Measure	1026	1034	patients
I-outcome-Measure	1035	1044	achieving
I-outcome-Measure	1045	1049	more
I-outcome-Measure	1050	1054	than
I-outcome-Measure	1055	1057	65
I-outcome-Measure	1057	1058	%
I-outcome-Measure	1059	1063	uNTx
I-outcome-Measure	1063	1064	/
I-outcome-Measure	1064	1066	Cr
I-outcome-Measure	1067	1076	reduction
O	1076	1077	,
B-outcome-Measure	1078	1082	time
I-outcome-Measure	1083	1085	to
I-outcome-Measure	1086	1090	more
I-outcome-Measure	1091	1095	than
I-outcome-Measure	1096	1098	65
I-outcome-Measure	1098	1099	%
I-outcome-Measure	1100	1104	uNTx
I-outcome-Measure	1104	1105	/
I-outcome-Measure	1105	1107	Cr
I-outcome-Measure	1108	1117	reduction
O	1117	1118	,
B-outcome-Measure	1119	1127	patients
I-outcome-Measure	1128	1140	experiencing
I-outcome-Measure	1141	1144	one
I-outcome-Measure	1145	1147	or
I-outcome-Measure	1148	1152	more
I-outcome-Measure	1153	1155	on
I-outcome-Measure	1155	1156	-
I-outcome-Measure	1156	1161	study
I-outcome-Measure	1162	1170	skeletal
I-outcome-Measure	1170	1171	-
I-outcome-Measure	1171	1178	related
I-outcome-Measure	1179	1185	events
I-outcome-Measure	1186	1187	(
I-outcome-Measure	1187	1190	SRE
I-outcome-Measure	1190	1191	)
O	1191	1192	,
O	1193	1196	and
B-outcome-Measure	1197	1203	safety
O	1204	1208	were
O	1209	1213	also
O	1214	1223	evaluated
O	1223	1224	.

O	1225	1227	At
O	1228	1233	study
O	1234	1238	week
O	1239	1241	13
O	1241	1242	,
O	1243	1246	the
B-outcome	1247	1253	median
I-outcome	1254	1261	percent
I-outcome	1262	1271	reduction
I-outcome	1272	1274	in
I-outcome	1275	1279	uNTx
I-outcome	1279	1280	/
I-outcome	1280	1282	Cr
O	1283	1286	was
B-iv-cont-median	1287	1289	71
I-iv-cont-median	1289	1290	%
O	1291	1294	for
O	1295	1298	the
O	1299	1305	pooled
O	1306	1315	denosumab
O	1316	1322	groups
O	1323	1326	and
B-cv-cont-median	1327	1329	79
I-cv-cont-median	1329	1330	%
O	1331	1334	for
O	1335	1338	the
O	1339	1341	IV
O	1342	1344	BP
O	1345	1350	group
O	1350	1351	.

O	1352	1359	Overall
O	1359	1360	,
B-iv-bin-percent	1361	1363	74
I-iv-bin-percent	1363	1364	%
O	1365	1367	of
O	1368	1377	denosumab
O	1377	1378	-
O	1378	1385	treated
O	1386	1394	patients
O	1395	1396	(
B-iv-bin-abs	1396	1399	157
O	1400	1402	of
B-intervention-participants	1403	1406	211
O	1406	1407	)
O	1408	1416	achieved
O	1417	1418	a
O	1419	1423	more
O	1424	1428	than
O	1429	1431	65
O	1431	1432	%
B-outcome	1433	1442	reduction
I-outcome	1443	1445	in
I-outcome	1446	1450	uNTx
I-outcome	1450	1451	/
I-outcome	1451	1453	Cr
O	1454	1462	compared
O	1463	1467	with
B-cv-bin-percent	1468	1470	63
I-cv-bin-percent	1470	1471	%
O	1472	1474	of
O	1475	1489	bisphosphonate
O	1489	1490	-
O	1490	1497	treated
O	1498	1506	patients
O	1507	1508	(
B-cv-bin-abs	1508	1510	27
O	1511	1513	of
B-control-participants	1514	1516	43
O	1516	1517	)
O	1517	1518	.

O	1519	1521	On
O	1521	1522	-
O	1522	1527	study
B-outcome	1528	1532	SREs
O	1533	1537	were
O	1538	1549	experienced
O	1550	1552	by
B-iv-bin-percent	1553	1554	9
I-iv-bin-percent	1554	1555	%
O	1556	1558	of
O	1559	1568	denosumab
O	1568	1569	-
O	1569	1576	treated
O	1577	1585	patients
O	1586	1587	(
B-iv-bin-abs	1587	1589	20
O	1590	1592	of
B-intervention-participants	1593	1596	211
O	1596	1597	)
O	1598	1604	versus
B-cv-bin-percent	1605	1607	16
I-cv-bin-percent	1607	1608	%
O	1609	1611	of
O	1612	1626	bisphosphonate
O	1626	1627	-
O	1627	1634	treated
O	1635	1643	patients
O	1644	1645	(
B-cv-bin-abs	1645	1650	seven
O	1651	1653	of
B-control-participants	1654	1656	43
O	1656	1657	)
O	1657	1658	.

O	1659	1661	No
O	1662	1669	serious
O	1670	1672	or
O	1673	1678	fatal
B-outcome	1679	1686	adverse
I-outcome	1687	1693	events
O	1694	1701	related
O	1702	1704	to
O	1705	1714	denosumab
O	1715	1723	occurred
O	1723	1724	.

O	1725	1737	Subcutaneous
O	1738	1747	denosumab
O	1748	1751	may
O	1752	1754	be
O	1755	1762	similar
O	1763	1765	to
O	1766	1768	IV
O	1769	1772	BPs
O	1773	1775	in
O	1776	1787	suppressing
O	1788	1792	bone
O	1793	1801	turnover
O	1802	1805	and
O	1806	1814	reducing
O	1815	1818	SRE
O	1819	1823	risk
O	1823	1824	.

O	1825	1828	The
O	1829	1835	safety
O	1836	1843	profile
O	1844	1847	was
O	1848	1858	consistent
O	1859	1863	with
O	1864	1866	an
O	1867	1875	advanced
O	1876	1882	breast
O	1883	1889	cancer
O	1890	1900	population
O	1901	1910	receiving
O	1911	1919	systemic
O	1920	1927	therapy
O	1927	1928	.
